Warner-lambert Company

Parke-davis Company

Other

Warmer-lambert Company LLC

Donald E Butler

Thomas N Nanninga

Alan Millar

Tung V Le

Bruce D Roth

Carl F Deering

Anthony J Thomas

Michael R Pavia

Timothy L Stuk

Michael Gerard Pamment

Jade Douglas Nelson

Fred M Hershenson

Randall Lee Dejong

Bruno P Poschel

Walter H Moos

Gary Jay Dozeman

John G Topliss

Yvon J L'Italien

Tung Van Le

Howard Yoshihisa Ando

James D Leonard

Barbara J Greenman

Haile Tecle

David Juergen Wustrow

John H Dodd

Ivan C Nordin

David M Lustgarten

Allan Millar

Jodette Gailey

William John Smith, Iii

Thomas E Jacks

Stephen G Hastings

Three-wheel, mobile frame adapted to secure one or more nozzles, wand, and spray control power, pressure washer to a main spar with a caster type front wheel assembly connected to the main spar and main wheel assembly comprising two axle mounted, main wheels. The spar includes a support leg attached at a point behind the main wheel assembly and descending downward to prevent inadvertent back-tipping of the three-wheel, mobile frame in response to cleaning fluid discharged against the flat surface to be cleaned under pressure from the nozzle when the unit is not fully controlled by the operator. Multiple nozzles may be attached to a nozzle that is attached to the wand in place of a single nozzle.

Three wheel, mobile frame

An improved process for the preparation of 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide by a novel synthesis is described where methyl cyanoacetate is converted in eight operations or fewer to the desired product, as well as other valuable intermediates used in the process.

[object Object]

Alcohol and water solvates of 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt are crystalline and have the formula wherein Ris H or lower alkyl, and x is a number from 0 to 10, and are useful for treating dyslipidemia.

Calcium dicarboxylate ethers, methods of making same, and treatment of vascular disease and diabetes therewith

Process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide

Alcohol and water solvates of 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt are crystalline and have the formula (I), wherein Ris H or lower alkyl, and x is a number from 0 to 10, and are useful for treating dyslipidemia.

An improved process for the preparation of 5-(4-fluorophenyl)-1-&lsqb;2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl&rsqb;-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide by a novel synthesis is described where methyl cyanoacetate is converted in eight operations or fewer to the desired product, as well as other valuable intermediates used in the process.

Process for the synthesis of 5-(4-fluorophenyl)-1-&lsqb;2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl&rsqb;-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide

Process for the synthesis of protected esters of

An improved process for the preparation of R(+)1,2,3,6-tetrahydro-4-phenyl-1-�(3-phenyl-3-cyclohexen-1-yl)methyl!pyri dine by a novel synthesis is described where 5-oxo-3-phenyl-3-cyclohexene-carboxylic acid is converted in five operations to the desired product, as well as processes for the resolution of 5-oxo-3-phenyl-3-cyclohexenecarboxylic acid using cinchonidine to afford (S)5-oxo-3-phenyl-3-cyclohexenecarboylic acid or .alpha.-chymotrypsin to selectively hydrolyze n-butyl 5-oxo-3-phenyl-3-cycohexenecarboxylate to afford (S)5-oxo-3-phenyl-3-cyclohexenecarboxylic acid as well as other valuable intermediates used in the processes.

Process for R (+)

An improved process for the preparation of trans-6- 2-(substituted-pyrrole-1-yl)alkyl!pyran-2-ones by a novel synthesis is described where .alpha.-metalated N,N-disubstituted acetamide is converted in seven operations to the desired products, and specifically, a process for preparing (2R-trans)-5-(4-fluorophenyl)-2-(1-methylethyl)-N, 4-diphenyl-1- 2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl!-1H-pyrrol e-3-carboxamide, as well as other valuable intermediates used in the processes and prodrugs which are bioconverted to hypolipidemic and hypocholesterolemic agents and pharmaceutical compositions of the same.

Process for trans-6- 2-(substituted-pyrrol-1-yl)alkyl!pyran-2-one

An improved process for the preparation of 9-(.beta.-D-arabinofuranosyl)adenine, 5'-phosphate, is described where dried 9-(.beta.-D-arabinofuranosyl)adenine is reacted with triethyl phosphate and phosphorous oxychloride in dichloromethane and the reaction mixture hydrolyzed and excess hydrogen chloride removed with propylene oxide as the acid scavenger. This process gives a yield of about 70-85%, which is nearly double the yields of the prior art.

Process for the synthesis of 9-(.beta.-D-arabinofuranosyl)adenine,

An improved process for the preparation of trans-6-[2-(substituted-pyrrole-1-yl)alkyl]pyran-2-ones by a novel synthesis is described where .alpha.-metalated N,N-disubstituted acetamide is converted in seven operations to the desired products, and specifically, a process for preparing (2R-trans)-5-(4-fluorophenyl)-2-(1-methylethyl)-N,4-diphenyl-1-[2-(tetrahy dro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-1H-pyrrole-3-carboxamide, as well as other valuable intermediates used in the processes and prodrugs which are bioconverted to hypolipidemic and hypocholesterolemic agents and pharmaceutical compositions of the same.

Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pyran-2-one

Process for trans-6[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one

An improved process for the preparation of trans-6-[2-(substituted-pyrrole-1-yl)alkyl]pyran-2-ones by a novel synthesis is described where .alpha.-metalated N,N-disubstituted acetamide is converted in seven operations to the desired products, and specifically, a process for preparing (2R-trans)-5-(4-fluorophenyl)-2-(1-methylethyl)-N,4-diphenyl-1-[2-(tetrahy dro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-1H pyrrole-3-carboxamide, as well as other valuable intermediates used in the processes and prodrugs which are bioconverted to hypolipidemic and hypocholesterolemic agents and pharmaceutical compositions of the same.

Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one

Growing community of inventors

Holland, MI, United States of America

Donald E Butler